Cowen Maintains Buy on Axsome Therapeutics (AXSM) Feb 2026
AXSM analyst rating: Cowen & Co. maintained a Buy on Axsome Therapeutics, Inc. (AXSM) on February 23, 2026. Cowen also raised its price target to $215 from $195, a move flagged in The Fly on the same day. The update followed the company’s Q4 2025 earnings call and coincided with a 7.3% move in the stock, equaling $12.67 since the change.
AXSM analyst rating: Cowen action and price target change
On February 23, 2026, Cowen & Co. kept its Buy rating on Axsome Therapeutics, Inc. (AXSM). Cowen raised the price target to $215 from $195, citing updated commercial assumptions and post-earnings clarity. The note was reported by The Fly and is available for reference source.
What the Cowen Buy means for investors
A maintained Buy signals continued analyst confidence in Axsome’s growth trajectory and revenue prospects. The higher price target implies ~10% upside from the prior target and reflects improved sales or margin expectations. Investors should see this as an analyst endorsement, not a guarantee, and weigh it against clinical and regulatory risks.
AXSM analyst rating in the context of recent results
Axsome’s Q4 2025 earnings call on February 23, 2026 likely informed Cowen’s stance. Management comments and guidance gave analysts clearer visibility on near-term revenue and launches. Read the earnings call transcript for details at Seeking Alpha source.
Market position, valuation and Meyka grade
Axsome’s market cap is $8,810,112,966, reflecting mid-cap biotech valuation. Meyka AI rates AXSM with a grade of B. This grade factors S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These inputs are part of our AI-powered market analysis and do not replace personal research.
Analyst coverage history and implications for consensus
Cowen’s update continues steady coverage of Axsome by biotech-focused analysts. While our entry records one recent action, investors should watch for follow-up notes from other firms. Multiple supportive analysts typically firm consensus estimates and can reduce short-term volatility, but divergence in price targets still signals differing risk assumptions.
How investors should interpret the AXSM analyst rating
Treat Cowen’s maintained Buy and higher price target as a positive signal for demand and execution. Balance that with Axsome’s pipeline risk, binary trial outcomes, and regulatory timelines. Use price targets as scenario guides, not absolute forecasts, and align any trade with time horizon and risk tolerance.
Final Thoughts
Cowen & Co.’s maintained Buy and higher $215 price target on Axsome Therapeutics, Inc. (AXSM) on February 23, 2026 provides a near-term positive signal for investors. The move reflects better clarity from the Q4 2025 earnings call and updated commercial assumptions. Meyka AI rates AXSM with a grade of B. This grade factors S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Investors should view the AXSM analyst rating as one input among many. Combine analyst views with company guidance, clinical timelines, and your risk profile before acting. Our platform provides real-time analyst tracking and AI price forecasts to help evaluate scenarios, but this does not constitute financial advice.
FAQs
What exactly changed in the AXSM analyst rating on February 23, 2026?
Cowen & Co. maintained its Buy on Axsome and raised the price target to $215 from $195 on February 23, 2026. The note followed the Q4 2025 earnings call and was reported by The Fly.
How does the AXSM analyst rating affect the stock price?
Analyst support can boost investor confidence and trading volume. Cowen’s update coincided with a 7.3% move in AXSM, or $12.67, showing short-term market sensitivity to price target revisions and analyst tone.
What does the Meyka grade mean for AXSM alongside the analyst rating?
Meyka AI rates AXSM with a grade of B, which blends benchmark comparison, sector performance, growth metrics, and analyst consensus. The grade is an analytic input, not investment advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.